Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Sitravatinib in Recurrent/Metastatic Cervical Cancer
NCT05614453Phase 2Withdrawn
- Sponsor
- Australia New Zealand Gynaecological Oncology Group
- Start
- Jun 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of sitravatinib, tislelizumab in Cervical Cancer (CC), sponsored by Australia New Zealand Gynaecological Oncology Group. Planned start Jun 2023; status: withdrawn.
02
Drugs
sitravatinibtislelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05614453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05614453.